| Name | Title | Contact Details |
|---|
Homology is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study Section of the NIH. Dr. Chatterjee and her team led the first adeno-associated virus (AAV) vector-mediated gene transfer studies into human hematopoietic stem cells and subsequently identified and isolated a series of naturally-occurring AAVs from human CD34+ cells.
Cantimer is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Labquip Ltd is a Woodbridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Ironwood Pharmaceuticals, we are committed to advancing the treatment of GI diseases and redefining the standard of care for GI patients. As a pioneer and champion in the development of a market-leading therapy for IBS-C and CIC, we are singularly focused on advancing the treatment of GI diseases and continue to challenge what has been done before to shape what the future holds. So, we named ourselves after the Ironwood tree, which can live for thousands of years in the harshest desert, creating a shaded microclimate in which life thrives. Iron, like science, is undeniable and strong. Wood, like artistry and humanity, is flexible, resilient and versatile. The two words together represent our passion for making a positive impact on the health – and lives- of GI patients, their families and communities.
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.